Galderma Group (SWX:GALD) Wins EU Nod For Restylane Shaype, Is It Fully Priced?
Restylane Shaype launch puts Galderma Group in focus
Galderma Group (SWX:GALD) has drawn fresh investor attention after securing European Union approval for Restylane Shaype, a hyaluronic acid gel designed specifically for minimally invasive chin shaping and augmentation.
See our latest analysis for Galderma Group.
The Restylane Shaype approval lands at a time when Galderma Group’s share price has eased in the very short term, with the 1 day and 7 day share price returns declining 3.11% and 4.60% respectively. However, the 90 day share price return of 10.44% and 1 year total shareholder return of 31.35% point to stronger underlying momentum over a longer window.
If this Restylane update has you thinking more broadly about aesthetic and healthcare trends, it could be a good moment to scan other opportunities through our healthcare focused AI stock screener at 133 healthcare AI stocks.
Bulls see Restylane Shaype and recent growth figures as support for Galderma Group’s premium valuation. Bears point to the recent share price pullback and relatively low value score. As you weigh valuation next, which side do the current numbers appear to support
Most Popular Narrative: 8.1% Undervalued
Galderma Group's most followed narrative points to a fair value of CHF188.31 per share versus the last close at CHF173. This gap sets up a valuation story built on growth expectations and margin expansion rather than short term share price moves.
The strong uptake and market share gains of newly launched products like Nemluvio and Relfydess, driven by their differentiated clinical profiles and positive physician reception, are likely to accelerate Galderma's top-line growth and expand the addressable market, especially as global population aging and heightened focus on appearance drive continued demand for dermatological and aesthetic treatments, positively impacting future revenues.
Want to see what is behind that growth story? The fair value rests on faster revenue expansion, rising margins and a richer product mix. Curious which specific forecasts power those assumptions and how long they are modeled to last? The full narrative lays out the numbers behind that CHF188.31 figure.
Result: Fair Value of CHF188.31 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Galderma Group narrative still faces pressure from reliance on Nemluvio and Relfydess, as well as softer injectable aesthetics demand, which could quickly test those valuation assumptions.
Find out about the key risks to this Galderma Group narrative.
Another view on Galderma Group’s valuation
The narrative points to Galderma Group trading at an 8.1% discount to a CHF188.31 fair value. Yet on earnings multiples, the picture is very different. The stock trades on a P/E of 57.5x versus a peer average of 35.8x and a fair ratio of 42.2x. This suggests the market is already paying a premium for growth and quality. How comfortable are you with that kind of valuation gap if expectations change?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With sentiment around Galderma Group pulling in both bullish and cautious views, it makes sense to move quickly and check the underlying data for yourself. To see what investors are optimistic about, start with the 3 key rewards.
Looking for more investment ideas beyond Galderma Group?
If Galderma Group has sharpened your focus on opportunities, now is the moment to widen your search with fresh ideas sourced from Simply Wall Street screeners.
- Spot potential growth stories early by checking out 226 elite penny stocks with strong financials. These already show stronger fundamentals than many expect from smaller stocks.
- Target value opportunities with solid quality by reviewing the 257 high quality undervalued stocks. These combine attractive pricing with robust underlying metrics.
- Prioritise resilience by scanning 302 resilient stocks with low risk scores. These score well on financial strength and business stability.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com